DLBCL stands for diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma. It is an aggressive cancer that develops from B-cells, a type of white blood cell that normally produces antibodies to fight infection. The word “diffuse” describes how the cancer cells spread in a scattered pattern through tissue rather than clustering into distinct nodules, and “large” refers to the size of the abnormal cells under a microscope. About 5.6 out of every 100,000 people are diagnosed each year, with a median age at diagnosis of 67.
How DLBCL Develops
B-cells go through several stages of maturation inside lymph nodes, particularly in structures called germinal centers. At any point during that process, genetic mutations can cause a B-cell to grow uncontrollably. The resulting cancer cells are large, and they spread in a diffuse pattern that destroys the normal architecture of the lymph node or whatever organ they invade.
These cancerous B-cells still carry surface proteins that identify them as B-cells, which is important for diagnosis and treatment. The most clinically relevant of these is a protein called CD20, because therapies can be designed to target it directly.
Common Symptoms
Most people notice a rapidly growing lump, often in the neck or abdomen. Other common signs include painless swelling in the neck, armpit, or groin. Many patients also experience what doctors call “B-symptoms”: unexplained fevers, drenching night sweats, and unintentional weight loss. Fatigue is also common. Because the cancer grows quickly, these symptoms tend to develop over weeks rather than months.
Where It Shows Up in the Body
DLBCL doesn’t always stay in the lymph nodes. In one study of early-stage patients, about two-thirds had disease that started outside the lymph nodes entirely. The most frequently affected sites were bone (21%), stomach (19%), testis (9%), intestine (8%), and breast (8%). This tendency to appear in unexpected locations can sometimes delay diagnosis, since the symptoms may initially point toward a problem with that specific organ rather than a blood cancer.
The Two Major Subtypes
Not all DLBCL behaves the same way. Gene expression testing divides most cases into two main subtypes based on which stage of B-cell development the cancer most closely resembles.
The germinal center B-cell (GCB) subtype resembles B-cells still maturing inside the germinal center. It generally responds better to standard treatment and carries a more favorable prognosis. However, roughly 20% of GCB patients still relapse after initial therapy, and relapse carries poor outcomes regardless of subtype.
The activated B-cell (ABC) subtype resembles B-cells that have already left the germinal center and become activated. This subtype is associated with worse outcomes and is harder to treat with standard chemotherapy. A key biological difference is that ABC tumors have a signaling pathway that is permanently switched on, driving continuous cell growth. Many newer targeted therapies are being developed specifically to shut down this pathway. About 10 to 15% of cases don’t fit neatly into either category and are classified as unclassifiable.
A particularly aggressive form called “double-hit” lymphoma occurs when the cancer carries two specific genetic rearrangements simultaneously. Double-hit cases are usually the GCB subtype and have very poor outcomes with standard treatment.
How It’s Diagnosed
Diagnosis requires a tissue biopsy, not just blood work. A pathologist examines the tissue under a microscope and uses a panel of staining tests to identify which proteins the cancer cells display on their surface. The key markers include CD20, CD10, BCL6, and MUM1. The pattern of which markers are present or absent helps determine the subtype (GCB vs. ABC) and guides treatment decisions. A marker called MIB-1 helps estimate how fast the cancer cells are dividing.
Standard Treatment
The backbone of DLBCL treatment is a combination regimen called R-CHOP, which pairs a targeted antibody with chemotherapy drugs and a steroid. The targeted antibody (rituximab) locks onto the CD20 protein on the cancer cells, flagging them for destruction by the immune system. The chemotherapy drugs attack rapidly dividing cells through different mechanisms, and the steroid helps reduce inflammation and enhances the effectiveness of the other drugs.
Most patients receive six cycles, each lasting three weeks, for a total treatment duration of about 18 weeks. Some cases require eight cycles depending on the extent of disease and how well it responds. Treatment is given in an outpatient infusion center, and patients typically go home the same day.
When Standard Treatment Doesn’t Work
For patients whose DLBCL comes back or doesn’t respond to initial therapy, CAR-T cell therapy has become an important option. This treatment involves collecting a patient’s own immune cells, genetically engineering them in a laboratory to recognize and attack the lymphoma, and then infusing them back into the patient. The process from cell collection to infusion typically takes several weeks. CAR-T therapy can cause significant side effects, including a severe immune reaction and neurological symptoms, so it is administered at specialized centers with experience managing these complications.
Outlook and Prognosis
Because DLBCL is aggressive, it grows quickly, but that rapid growth also makes it vulnerable to treatment. A significant proportion of patients are cured with first-line therapy, particularly those with the GCB subtype and limited-stage disease. Prognosis depends on several factors: the molecular subtype, how far the disease has spread at diagnosis, the patient’s age and overall health, and specific genetic features of the tumor. Patients whose cancer relapses after initial treatment face a more difficult road, though newer therapies like CAR-T cells have expanded the options considerably.